ROCKVILLE, Md.,
Feb. 13, 2020 /PRNewswire/
-- Synthetic Biologics, Inc. (NYSE American: SYN), a
diversified clinical-stage company leveraging the microbiome to
develop therapeutics designed to prevent and treat gastrointestinal
(GI) diseases in areas of high unmet need, intends to report
operational highlights and financial results for the year ended
December 31, 2019 on Thursday, February 20, 2020, and will host a
conference call the same day at 4:30 p.m.
ET. The dial-in information for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280
Participants are asked to dial in 15 minutes before the start of
the call to register. The call will also be webcast over the
Internet at https://www.webcaster4.com/Webcast/Page/1096/32979. An
archived replay of the call will be available for approximately
ninety (90) days at the same URL,
https://www.webcaster4.com/Webcast/Page/1096/32979 beginning
approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a
clinical-stage company developing therapeutics that preserve the
microbiome to protect and restore the health of patients. The
Company's lead candidates are: (1) SYN-004 (ribaxamase) which is
designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to
prevent microbiome damage, C. difficile infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial
resistance (AMR) and acute graft-versus-host-disease (aGVHD) in
allogeneic hematopoietic cell transplant (HCT) recipients, and (2)
SYN-010, which is intended to reduce the impact of
methane-producing organisms in the gut microbiome to treat an
underlying cause of irritable bowel syndrome with constipation
(IBS-C). The Company is also advancing SYN-020, an oral formulation
of the enzyme intestinal alkaline phosphatase (IAP) to treat both
local GI and systemic diseases, and has completed proof-of-concept
studies with monoclonal antibody therapies for the prevention and
treatment of pertussis. For more information, please visit
Synthetic Biologics' website at
www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2019-year-end-operational-highlights-and-financial-results-on-february-20-2020-301004285.html
SOURCE Synthetic Biologics, Inc.